Abstract:Abstract Forkhead box protein M1 (FOXM1) is often overexpressed in human cancers and strongly associated with therapy resistance and less good patient survival. The chemotherapy options for patients with the most aggressive types of solid cancers remain very limited because of the acquired drug resistance, making the therapy less effective. NPM1 mutation through the inactivation of FOXM1 via FOXM1 relocalization to the cytoplasm confers more favorable treatment outcomes for AML patients, confirming FOXM1 as a crucial target to overcome drug resistance. Pharmacological inhibition of FOXM1 could be a promising approach to sensitize therapy-resistant cancers. Here, we explore a novel FOXM1 inhibitor STL001, a first-generation modification drug of our previously reported FOXM1 inhibitor STL427944. STL001 preserves the mode of action of the STL427944; however, STL001 is up to 50 times more efficient in reducing FOXM1 activity in a variety of solid cancers. The most conventional cancer therapies studied here induce FOXM1 overexpression in solid cancers. The therapy-induced FOXM1 overexpression may explain the failure or reduced efficacy of these drugs in cancer patients. Interestingly, STL001 increased the sensitivity of cancer cells to conventional cancer therapies by suppressing both the high-endogenous and drug-induced FOXM1. Notably, STL001 does not provide further sensitization to FOXM1-KD cancer cells, suggesting that the sensitization effect is conveyed specifically through FOXM1 suppression. RNA-seq and gene set enrichment studies revealed prominent suppression of FOXM1-dependent pathways and gene ontologies. Also, gene regulation by STL001 showed extensive overlap with FOXM1-KD, suggesting a high selectivity of STL001 toward the FOXM1 regulatory network. A completely new activity of FOXM1, mediated through steroid/cholesterol biosynthetic process and protein secretion in cancer cells was also detected. Collectively, STL001 offers intriguing translational opportunities as combination therapies targeting FOXM1 activity in a variety of human cancers driven by FOXM1.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: **Develop a new FOXM1 inhibitor, STL001, to overcome the resistance of multiple human cancers to traditional chemotherapeutic drugs and improve the efficacy of these chemotherapeutic drugs**. ### Background and Problems 1. **The role of FOXM1 in cancer**: - Forkhead box protein M1 (FOXM1) is a transcription factor that is over - expressed in multiple human cancers and is closely related to treatment resistance and poor patient survival rates. - High levels of FOXM1 are usually associated with the resistance of chemotherapeutic drugs, leading to a decrease in the effectiveness of traditional treatment methods. 2. **Limitations of existing chemotherapeutic drugs**: - Chemotherapy is the main method for treating cancer, but many cancer types (especially invasive solid tumors) have limited chemotherapy effectiveness due to acquired resistance. - Traditional anti - cancer drugs such as 5 - FU, cisplatin, paclitaxel, etc. can cause over - expression of FOXM1 in some cases, further exacerbating the resistance. 3. **The potential of FOXM1 as a target**: - Inhibiting the activity of FOXM1 may be an effective strategy to restore the sensitivity of cancer cells to chemotherapeutic drugs. - Through network - centered transcriptome analysis, researchers have discovered some small - molecule inhibitors of FOXM1, but their effectiveness and selectivity still need to be improved. ### Research Objectives - **Develop a new FOXM1 inhibitor, STL001**: - STL001 is the first - generation improved drug after structural optimization based on the previously reported FOXM1 inhibitor STL427944. - Compared with STL427944, STL001 shows higher efficiency in reducing FOXM1 activity and has better drug properties. - **Verify the anti - tumor effect of STL001**: - Researchers tested the anti - tumor effect of STL001 in multiple human cancer cell lines, including ovarian cancer, colorectal cancer, breast cancer, esophageal cancer, and prostate cancer. - The results show that STL001 can significantly reduce the FOXM1 protein level in these cell lines and enhance the sensitivity of cancer cells to multiple traditional chemotherapeutic drugs. - **Explore the mechanism of action of STL001**: - Through RNA - seq and gene set enrichment analysis, researchers found that STL001 mainly exerts its anti - tumor effect by inhibiting FOXM1 - dependent signaling pathways. - STL001 also induces the translocation of FOXM1 from the nucleus to the cytoplasm and promotes its autophagic degradation. ### Main Findings - **The effectiveness of STL001 in multiple cancer cells**: - STL001 can significantly reduce the FOXM1 protein level at a low concentration, and its effect is 25 to 50 times stronger than that of STL427944. - STL001 can enhance the sensitivity of cancer cells to multiple traditional chemotherapeutic drugs, including cisplatin, doxorubicin, 5 - FU, irinotecan, and paclitaxel, etc. - **The mechanism of action of STL001**: - STL001 inhibits FOXM1 activity by inducing the translocation of FOXM1 from the nucleus to the cytoplasm and autophagic degradation. - RNA - seq analysis shows that STL001 is highly selective for the FOXM1 - regulated gene network, and its effect is similar to that of FOXM1 knockdown. ### Conclusions - **STL001, as a new FOXM1 inhibitor**, shows good anti - tumor effects in multiple human cancers and can significantly improve the sensitivity of cancer cells to traditional chemotherapeutic drugs. - This finding provides a new strategy for overcoming chemotherapy resistance and lays the foundation for further clinical evaluation.

Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies

Abstract P1-19-02: Repurposing the FOXO4 senolytic against triple-negative breast cancer

FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation

FOXM1: a potential therapeutic target in human solid cancers

Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer

FoxM1 Mediated Resistance to Gefitinib in Non-Smallcell Lung Cancer Cells

Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer

The Promise of Combination Therapies with FOXM1 Inhibitors for Cancer Treatment

Abstract 3031: Overcoming drug resistance in cancer: A paradigm shift with FoxM1 targeting

FOXM1 modulates docetaxel resistance in prostate cancer by regulating KIF20A

FOXO1 Negates the Cooperative Action of FOXL2C134W and SMAD3 in CYP19 Expression in HGrC1 Cells by Sequestering SMAD3

FOXM1 Overexpression is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer and Mediates Sensitivity to Cisplatin in A549 Cells Via the JNK/mitochondrial Pathway.

Novel benzothiazole/benzothiazole thiazolidine‐2,4‐dione derivatives as potential FOXM1 inhibitors: In silico, synthesis, and in vitro studies

Targeting the CtBP1-FOXM1 transcriptional complex with small molecules to overcome MDR1-mediated chemoresistance in osteosarcoma cancer stem cells

FOXM1 promotes the progression of non-small cell lung cancer by inhibiting miR-509-5p expression via binding to the miR-509-5p promoter region

Gefitinib selectively targets non-small cell lung cancer cells through inhibition of Forkhead box M1

Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs

Identification of FOXM1 As a Specific Marker for Triple‑negative Breast Cancer

Highly Expressed FOXF1 Inhibit Non-Small-Cell Lung Cancer Growth via Inducing Tumor Suppressor and G1-Phase Cell-Cycle Arrest

The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance

Abstract B010: Development of folate receptor alpha targeted FOXM1 inhibitors for ovarian cancer